Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1353 results about "Ce Antibody" patented technology

Monoclonal antibody combination for detecting cat FGF23 protein and application

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat FGF23 protein and application. The invention provides a monoclonal antibody combination with high specificity and strong sensitivity aiming at cat FGF23 protein. The antibody combination comprises monoclonal antibodies 5A2 and 3A1. By designing and optimizing complementary determining region (CDR) sequences of heavy chain and light chain variable regions, CDR amino acid sequences are respectively shown as SEQ ID NO.1 to SEQ ID NO.12, and the antibody combination has excellent binding activity and detection specificity. A double-antibody sandwich ELISA detection method constructed on the basis of the antibody combination has relatively high sensitivity, and the accuracy of a detection result is remarkably improved.
Owner:BEIJING SUBENYUANHE BIOTECHNOLOGY CO LTD

Preparation method and application of chicken P4HB protein polyclonal antibody

The invention discloses a preparation method and application of a rabbit anti-chicken P4HB protein polyclonal antibody, and the preparation method comprises the following steps: amplifying a chicken P4HB gene by using a PCR (Polymerase Chain Reaction) method, and carrying out homologous recombination on the chicken P4HB gene into a pCOLDII carrier to construct a prokaryotic recombinant expression plasmid pCOLDII-P4HB; the recombinant plasmid is converted into E.coli BL21 (DE3), IPTG is used for induction expression, a Ni-NTA affinity chromatography method is used for protein purification, purified HIS-P4HB protein and an isometric Freund's complete adjuvant are mixed and emulsified, a New Zealand white rabbit is immunized with the purified protein, neck and back multi-point subcutaneous injection is adopted, and the antibody is cryopreserved in a-80 DEG C refrigerator after being subjected to Protein A + G affinity chromatography purification. The prokaryotically expressed HIS-P4HB protein is expressed in a competent cell supernatant, and the molecular mass is about 25KDa; after an experimental rabbit immunizes the P4HB recombinant protein for four times, blood sampling and serum separation are carried out, and after purification, the antibody can identify expression and cell localization of native conformation and linearized P4HB protein through Western blot and IF.
Owner:YANGZHOU UNIV

Monoclonal antibody against NMP22 as well as preparation method and application of monoclonal antibody

The invention belongs to the field of antibodies, and particularly relates to an anti-NMP22 monoclonal antibody as well as a preparation method and application thereof. The invention provides CDR sequences of a heavy chain variable region and a light chain variable region of an anti-NMP22 antibody, the antibody can specifically recognize nuclear matrix protein 22 (NMP22), has high affinity and high specificity to the protein, can be applied to diagnosis of diseases related to abnormal urine nuclear matrix protein 22 level, and especially can be applied to clinical diagnosis of bladder cancer.
Owner:NANJING GENSCRIPT BIOTECH CO LTD

Cancer immunotherapy by disrupting PD-1 / PD-l1 signaling

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Owner:BRISTOL MYERS SQUIBB CO

Antibody pair, reagent and method for detecting HIV P24

The invention discloses an antibody pair, a reagent and a method for detecting HIV P24, and relates to the field of immunodiagnosis. The antibody pair for detecting the HIV P24 disclosed by the invention comprises the first antibody and the second antibody. The reagent and the detection method based on the antibody pair can accurately detect the existence of the HIV P24.
Owner:DONGGUAN PENGZHI BIOTECH CO LTD

Anti-PD-L1 antibody coupling medicine and preparation method thereof

The invention discloses an anti-PD-L1 antibody coupling drug and a preparation method thereof, belongs to the field of biological medicines, and is used for preparing anti-cancer drugs. The antibody coupling medicine is formed by coupling an anti-PD-L1 antibody and a payload through a linker, a light chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 1, a heavy chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 2, the payload is an avixatecan derivative Dxd, and the ratio (DAR) of the payload to the antibody is 6-8. The antibody-conjugated drug has a better killing effect on PD-L1 positive tumor cells of human and dogs, and has fewer dimers and higher thermal stability at a high DAR value (DAR6-8), and an accelerated stability test shows that the antibody-conjugated drug has good structural stability and binding activity.
Owner:WENZHOU MEDICAL UNIV +1

A monoclonal antibody combination for detecting cat NT-proBNP protein and its application

This invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody combination for detecting feline NT-proBNP protein and its applications. The monoclonal antibody combination of the present invention comprises monoclonal antibodies 3A6 and 5H5. These two antibodies possess unique heavy and light chain variable region complementarity-determining regions, respectively, and their amino acid sequences have been fully defined (SEQ ID NOs. 1-12). This antibody combination can specifically recognize and efficiently bind to feline NT-proBNP protein, making it suitable for the development of a highly sensitive and specific diagnostic tool for feline cardiomyopathy. By constructing a double-antibody sandwich ELISA assay system, the minimum detection limit can reach 100 pg / mL, and it exhibits excellent specificity and stability.
Owner:BEIJING SUBENYUANHE BIOTECHNOLOGY CO LTD

Cancer immunotherapy by disrupting PD-1 / PD-l1 signaling

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Owner:BRISTOL MYERS SQUIBB CO

Antibody for resisting CD19 on porcine B cell surface or antigen binding fragment thereof as well as composition and application thereof

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.
Owner:INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT

Anti-human albumin antibody 5H11 and application thereof

The invention belongs to the field of immunological detection, and provides an anti-human albumin antibody 5H11 and application thereof. The anti-human albumin antibody provided by the invention can be specifically combined with human albumin and has relatively high stability. Based on the antibody, a kit capable of accurately, rapidly and massively detecting the content of HSA in a sample is developed. The double-antibody sandwich ELISA method for detecting the human albumin has high sensitivity, specificity and accuracy, can realize accurate and high-throughput detection of the content of albumin in human serum or other serum-like species containing the human albumin, and has a good application prospect in detection of the human albumin.
Owner:BEIJING SOLARBIO TECH CO LTD

Antibodies for binding PSMA with reduced affinity for neonatal fc receptor

To provide a modified antibody of class IgG for use in radioimmunotherapy.SOLUTION: An anti-PSMA antibody comprises a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modifications having the effect of reducing FcRn binding are selected from positions His310, His433, His435, His436, and Ile253. The antibodies of the present invention are particularly suited for use in radioimmunotherapy.SELECTED DRAWING: None
Owner:TELIX PHARM (INNOVATIONS) PTY LTD

Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use

The present disclosure relates HER2 antibodies and to the de novo design of structure-based design targeted antibodies. According to the current disclosure, computer-implemented methods of designing an antibody sequences that will bind the HER2 with significant affinity at a target receptor epitope are disclosed. The method utilizes artificial intelligence (Al) and machine learning (ML) models that are trained to predict improved biomolecule (e.g., antibody or antibody fragments) binding sequences or other desirable properties using known biomolecule / binding partner complexes. A designed HER2 antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.
Owner:ABSCI CORPORATION

Cancer immunotherapy by disrupting PD-1 / PD-l1 signaling

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Owner:BRISTOL MYERS SQUIBB CO

Anti-human CD89 antibodies and uses thereof

The invention discloses an antibody that can bind an extra-cellular part of human CD89 (human FcαRI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells and that induces less cell death in said human CD89 expressing cells when compared to the antibody MIP8a. The invention also disclosed the use of such antibodies in combating certain diseases.
Owner:JJP BIOLOGICS SP ZOO

Antibody or antigen binding fragment thereof as well as related products and application thereof

The invention discloses an antibody or an antigen binding fragment thereof and a related product and application thereof, and relates to the field of immunodetection, the antibody comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is shown as SEQ ID NO: 28 and LCDR1, LCDR2 and LCDR3 in a light chain variable region of which the amino acid sequence is shown as SEQ ID NO: 29, the antibody can be specifically combined with HPV18 type E6-E7 fusion protein, and the antibody can be used for detecting the HPV18 type E6-E7 fusion protein. The method has the advantages of high detection sensitivity, good specificity, high accuracy, good repeatability and the like, and provides a way for effective detection of the HPV18 type E6-E7 fusion protein.
Owner:CHENGDU HUARENKANG BIOTECHNOLOGY CO LTD

Antibody and kit for targeting human desmomere glycoprotein 2

The invention discloses an antibody and a kit for targeting human desmogranuloprotein 2. The antibody comprises a light chain variable region and a heavy chain variable region, the heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody has high affinity with deodontoprotein-2, and a kit developed by using the antibody can realize high-sensitivity quantitative detection of DSC2, thereby not only being beneficial to basic research, but also being capable of providing valuable reference information for clinical diagnosis.
Owner:SHANGHAI RNACURE BIOPHARMA CO LTD

Anti-serum albumin nanobody and derivative thereof

The present invention relates to a nanobody or antigen-binding fragment thereof that specifically binds to serum albumin, a derivative comprising the nanobody or the antigen-binding fragment thereof, a nucleic acid encoding the antibody or antigen-binding fragment thereof, a host cell comprising same, and related uses. Further, the present invention relates to therapeutic use of the antibody or the antigen-binding fragment thereof or the derivative.
Owner:BIOTHEUS INC

Anti-DLL3 antibody and application

Provided are antibodies against DLL3, antibody-drug conjugates comprising the antibodies, and methods of diagnosis and treatment of diseases associated with the expression of DLL3, such as cancer.
Owner:CSPC MEGALITH BIOPHARMACEUTICAL CO LTD

Humanized antibodies or functional fragments thereof against tumor antigens

There is provided an antibody or fragment thereof wherein the antibody comprises: (a) a heavy chain variable region (VH) wherein the VH comprises a complementarity determining region (CDR) selected from the group consisting of (i) H-CDR1, H-CDR2 and H-CDR3 as shown in any one of SEQ ID NO.1 to 24 or 49 to 88, respectively, and / or (b) a light chain variable region (VL) wherein the VH comprises a complementary determining region (CDR) selected from the group consisting of: (i) H-CDR1, H-CDR2 and H-CDR3 as shown in any one of SEQ ID NO.1 to 24 or 49 to 88; wherein the VL comprises a complementarity determining region (CDR) selected from the group consisting of: (i) L-CDR1, L-CDR2, and L-CDR3 as shown in any one of SEQ ID NO.25 to 48 or 89 to 128, respectively. Preferably, both VH and VL chains are used. Antibodies and fragments thereof have utility in the treatment of cancer.
Owner:BIONTECH SE

Anti-DLL3 antibody and use

Provided are an anti-DLL3 antibody, an antibody-drug conjugate comprising the antibody, and a diagnosis and treatment method for a disease related to expression of DLL3, such as cancer.
Owner:CSPC MEGALITH BIOPHARMACEUTICAL CO LTD

Anti-human albumin antibody 7G7, antibody composition and application thereof

The invention belongs to the field of immunological detection, and provides an anti-human albumin antibody 7G7, an antibody composition and application thereof. The anti-human albumin antibody provided by the invention can be specifically combined with human albumin and has relatively high stability. Based on the antibody, a kit capable of accurately, rapidly and massively detecting the content of HSA in a sample is developed. The double-antibody sandwich ELISA method for detecting the human albumin has high sensitivity, specificity and accuracy, can realize accurate and high-throughput detection of the content of albumin in human serum or other serum-like species containing the human albumin, and has a good application prospect in detection of the human albumin.
Owner:BEIJING SOLARBIO TECH CO LTD

Preparation and application of African swine fever virus p30 protein monoclonal antibody

The invention relates to the technical field of antibodies, in particular to an anti-African swine fever virus p30 protein monoclonal antibody and application thereof, and the anti-African swine fever virus p30 protein monoclonal antibody can be specifically combined with African swine fever virus p30 protein. The anti-ASFV p30 protein monoclonal antibody is prepared by immunizing a BALB / c mouse through an immunological method, and the antibody is high in specificity, titer and affinity and can be applied to immunological detection or antibody detection kits.
Owner:CHINA INST OF VETERINARY DRUG CONTROL

Mouse anti-bovine IgG monoclonal antibody B4 and application thereof

The invention relates to the technical field of livestock immunology, in particular to a mouse anti-bovine IgG monoclonal antibody and application thereof. The mouse anti-bovine IgG monoclonal antibody provided by the invention can be specifically combined with bovine IgG, has no cross reaction with other similar proteins, has relatively high affinity with bovine IgG, and has relatively high stability; based on the antibody, a double-antibody sandwich ELISA method for detecting bovine IgG has high sensitivity, specificity and accuracy, accurate and high-throughput detection of the IgG content in bovine serum or other serum analogues or products containing bovine IgG can be realized, and the antibody has a good application prospect in bovine IgG detection.
Owner:BEIJING SOLARBIO TECH CO LTD

A camelid single-domain antibody against crp and its preparation method and application

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.
Owner:BEIJING 3S CENTURY TECH CORP

Antibody against p-TAU 217 and use thereof

The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.
Owner:XIAMEN UNIV

Antibody aiming at severe fever with thrombocytopenia syndrome virus glycoprotein and application thereof

The monoclonal antibody of the glycoprotein Gn of the severe fever with thrombocytopenia syndrome virus is screened on the basis of immune repertoire sequencing, and the biological characteristics of the monoclonal antibody are identified. The method comprises the following steps: taking purified SFTSV-Gn as bait, taking virus specific B cells from an immunized female BALB / c mouse B cell bank, selecting an antibody sequence with potential binding activity by utilizing a 10 * immune repertoire sequencing method in combination with bioinformatics analysis, constructing the antibody sequence to an eukaryotic expression vector pcDNA3.4, expressing and purifying a monoclonal antibody, and identifying the biological activity of the monoclonal antibody. 14 antibodies are selected from 3544 captured B cells, functional verification shows that 12 antibodies can be combined with SFTSV-Gn glycoprotein, and the Gn-5 antibody and the Gn-7 antibody have high combining capacity; western blot, indirect immunofluorescence test and flow cytometry prove that the antibody can specifically recognize the SFTSV, the effective concentration is as low as 2 mu g / mL, and a foundation is laid for development of a rapid diagnosis reagent for the SFTSV.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Development and use of novel immunomodulator

Provided is the development and use of a novel immunomodulator. The immunomodulator is an antibody or an antigen-binding portion thereof that binds to CCR8. The antibody has a neutralizing activity in blocking CCL1 / CCR8 axis, can inhibit CCL1-induced cell activation, and for low-affinity FcγRIIIA158F allele carriers in the population, enhances the ADCC effect by means of Fc optimization.
Owner:BEIJING TIANNUOJIANCHENG PHARMA TECH CO LTD

C1q antibody and application thereof, medicament for inhibiting classical pathway activation of complement and application of medicament

The invention relates to the technical field of biomedicine, in particular to a C1q antibody and application thereof, and a medicament for inhibiting classical pathway activation of complement and application thereof. The C1q antibody comprises a VHCDR1, a VHCDR2 and a VHCDR3 of which the amino acid sequences are shown as SEQ ID NO: 1 to SEQ ID NO: 3, and a VLCDR1, a VLCDR2 and a VLCDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 to SEQ ID NO: 6. The antibody has good affinity with C1q antigen, and can effectively inhibit classical pathway activation of complement.
Owner:JIANGSU TAIZHOU PEOPLES HOSPITAL

Anti-claudin 18.2 antibody, Anti-claudin 18.2 antibody-drug conjugate, and use thereof

The present invention relates to an antibody or an antigen-binding fragment thereof binding to CLDN18.2, an antibody-drug conjugate comprising same, and a use of the antibody and the antibody-drug conjugate. An anti-CLDN18.2 monoclonal antibody according to the present invention comprises a fully human antibody sequence, thereby having low in vivo immunogenicity, and exhibits excellent antigen affinity and binding ability specific to a low expression to a high expression level of the CLDN18.2 protein. Thus, the antibody is expected to exhibit high specificity and safety as an antibody-based therapeutic agent such as in the form of a monoclonal antibody and / or an antigen-binding fragment (scFv), an antibody-drug conjugate (ADC), an immune cell engager, a chimeric antigen receptor (CAR), a multispecific antibody, and the like. In addition, the antibody according to the present invention may undergo cellular internalization, enables an anti-CLDN18.2 antibody-drug conjugate comprising said antibodies to be conveniently prepared, and has excellent yield and quality and thus is expected to be highly likely to be developed as a drug. A drug conjugate comprising the anti-CLDN18.2 antibody according to the present invention has excellent in vivo anticancer efficacy and has an expanded therapeutic index (TI) and thus is expected to be usefully employable for the treatment and / or prevention of cancer diseases expressing CLDN18.2 and related diseases.
Owner:TRIOAR INC

Antibody composition and application thereof for detecting multiple myeloma based on full spectrum flow cytometry

The present invention provides an antibody composition for detecting multiple myeloma based on full-spectrum flow cytometry and its application, belonging to the technical field of multiple myeloma detection. The antibody composition includes CD3 antibody, CD20 antibody, HLA-DR antibody, CD8 antibody, CD11b antibody, CD10 antibody, CD71 antibody, CD28 antibody, CD14 antibody, CD13 antibody, Igκ antibody, CD15 antibody, Igλ antibody, CD117 antibody, CD56 antibody, CD45 antibody, CD19 antibody, CD34 antibody, CD138 antibody, CD4 antibody, CD38 antibody, CD22 antibody and CD27 antibody. The kit containing the antibody composition can be applied to a full-spectrum flow cytometer to accurately perform preliminary screening on patients with multiple myeloma.
Owner:WUHAN KANGSHENGDA MEDICAL LAB CO LTD